Long-term follow-up of a drug for children with neurofibromatosis type 1
Treatments studied
Part of Brain & nervous system, Cancer, Genetic & congenital clinical trials.
This study continues to check the safety and how well the study drug FCN-159 works over a longer time in children who already took part in the earlier FCN-159-002 study. It helps doctors understand the long-term effects of the treatment for neurofibromatosis type 1.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been part of the earlier FCN-159-002 study for children with neurofibromatosis type 1.
- You must be willing to take part in this long-term follow-up and sign a consent form.
- You must not have any health problems or other issues that would make it unsafe or hard to join the study.
- You must be able to keep up with the study visit schedule.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests HL-085 in adults with neurofibromatosis type 1 (NF1) who have a nerve tumor (plexiform neurofibroma) that cannot be removed by surgery and causes symptoms. It aims to shrink or control the tumor by measuring changes on MRI and monitoring side effects.
This study tests whether the drug selumetinib can prevent the growth of plexiform neurofibromas (nerve tumors) in young children with NF1. Children are first monitored with MRI scans, and if a tumor appears or grows, they may receive treatment.
This trial tests a combination of two targeted drugs (cabozantinib and selumetinib) for people with NF1 who have plexiform neurofibromas that are growing or causing significant problems. The goal is to see if this combination can shrink or slow the growth of these tumors.
This study monitors people with neurofibromatosis type 1 (NF1) over time to watch for signs that their nerve tumors might turn into cancer. It helps researchers learn which tumors are more likely to change and may lead to better care.
This trial tests a capsule medication (smetinib) for people with type 1 neurofibromatosis (NF1) who have tumors that can be surgically removed but have not spread to vital areas like the brain or spine. The goal is to see if the drug can help shrink or control these tumors.
This trial tests a new pill (smeitinib) to shrink tumors caused by neurofibromatosis type 1 (NF1). It is for adults with NF1 who have tumors that cannot be removed by surgery, including those that press on the brain or spine.
Hear when a new Neurofibromatosis 1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.